1
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
Condition(s):Chemotherapy-induced Nausea and VomitingLast Updated:June 7, 2018Terminated
Fosaprepitant as an Intervention: 164 Clinical Trials, Page 1 of 17
Hide Studies Not Open or Pending
2
Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant as PONV Prevention
Condition(s):Postoperative Nausea and Vomiting; Gynecologic Surgical Procedures; LaparoscopyLast Updated:April 25, 2023Not yet recruiting
3
Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy
Condition(s):Non-small Cell Lung Cancer; Vomiting; Nausea; EmesisLast Updated:April 3, 2015Unknown status
4
Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic Drugs
Condition(s):Chemotherapy Induced Nausea and Vomiting Pediatric Cancer PatientsLast Updated:February 9, 2022Not yet recruiting
5
Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
Condition(s):Nasopharyngeal CarcinomaLast Updated:November 7, 2022Completed
6
Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia
Condition(s):Postoperative NauseaLast Updated:July 18, 2022Completed
7
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
Condition(s):Chemotherapy-induced Nausea and VomitingLast Updated:September 23, 2021Completed
8
Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study
Condition(s):Solid Tumor Patients Receiving High Emetic Risk Multi-day ChemotherapyLast Updated:September 2, 2020Unknown status
9
Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.
Condition(s):NeoplasmsLast Updated:March 6, 2023Recruiting
10
Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients – SENRI Trial
Condition(s):Colorectal CancerLast Updated:February 26, 2021Completed